2020-12-13 Comments Off on Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis DURHAM, N.C.–(BUSINESS WIRE)–December 9, 2020 — Mycovia Pharmaceuticals, Inc. (“Mycovia”),